Jefferies Boosts Price Target, Estimates on Pfizer (PFE)

Due to an expected big year for clinical drug results, Jefferies analysts increased the price target and earning estimates on pharmaceutical company Pfizer Inc. (PFE).

The analysts maintain a “Buy” rating for PFE and now see shares reaching $31, suggesting a +16.4% upside to Tuesday’s closing price of $26.62.

Pfizer shares were down slightly during premarket trading on Wednesday. The stock is up +21.89% over the past year.

The Bottom Line
We have been recommending shares of Pfizer (PFE) since Mar.2, 2012, when the stock was trading at $21.49. The company has a 3.61% dividend yield, based on last night’s closing stock price of $26.62.

Pfizer Inc. (PFE) is recommended at this time, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here